Stock listing

Sino Biopharmaceutical Limited

Selected listing: 1177 · HKEX · HKD · HK

Sino Biopharmaceutical Limited (HKEX:1177), Health Technology. Latest release Oct 2, 2026: MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES…

1177:HKEXHKDHKUpdated October 2, 2026

Ticker: HKEX:1177
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: HKEX
Currency: HKD

About Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited, traded under the ticker 1177 on the Hong Kong Stock Exchange, is a public company focused on the development and manufacturing of pharmaceutical products. Sino Biopharmaceutical aims to enhance healthcare solutions through innovative research and development initiatives.

Latest news from Sino Biopharmaceutical Limited

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 SEPTEMBER 2026

October 1, 2026

VOLUNTARY ANNOUNCEMENT - ENTER INTO STRATEGIC BIOSIMILARS PARTNERSHIP WITH STADA

September 28, 2026

Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion

August 19, 2026

Sino Biopharmaceutical : Once-Yearly Dosing, Targeting Cardiovascular Disorders, First US Patient Enrolled in China-US Phase II Clinical Trial of Hygieia's Kylo-11

April 9, 2026

Sino Biopharm Releases 2025 Annual Results: Revenue and Net Profit Maintain Double-Digit Growth, Innovative Product Revenue Exceeds RMB 15 Billion

March 26, 2026

All Sino Biopharmaceutical Limited news →

Research Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited company profile

View the public company page for Sino Biopharmaceutical Limited on 6ix.

Sino Biopharmaceutical Limited news

Read company news and market updates connected to Sino Biopharmaceutical Limited.

Sino Biopharmaceutical Limited investor events

Find investor webinars, events, and replay context for Sino Biopharmaceutical Limited.